Abstract: Equine myotonic dystrophy (eMD) is a rare neuromuscular disorder of undetermined origin marked by muscle hypertrophy and stiffness, dystrophic muscle histopathology, and myotonic discharges. In humans, myotonic dystrophy (DM) arises from trinucleotide repeat expansions in dystrophia myotonica protein kinase (DMPK) (DM1) or tetranucleotide expansions in cellular nucleic acid-binding protein (CNBP) (DM2), which disrupt mRNA processing and induce embryonic splicing patterns across multiple genes. In 6 eMD Quarter Horse types, (2-36 months-of-age) and 8 control Quarter Horses we determined: (1) fiber type composition of triceps, gluteal, and semimembranosus muscles; (2) differential gene (DEG) and protein (DEP) expression using transcriptomic and proteomic analyses; (3) presence of repeat expansions in transcripts of DMPK or CNBP and (4) exon 7 retention in CLCN1 or exon 22 splicing in ATP2A1. Predominance and clustering of type 1 fibers, expression of embryonic myosin, and upregulated mitochondrial and sarcomeric DEPs characterized eMD hindlimb musculature. Gene ontology (GO) analysis of 730 upregulated DEGs identified numerous GO terms related to morphogenesis of mesoderm-derived tissues and upregulated genes impacting myoD expression in eMD muscle. Top upregulated DEG involved myogenesis (MYOZ2, SBK2, SBK3, PAMR1), neurons, transcription/translation, cytoskeleton, basement/plasma membranes, and calcium binding/transport. Top upregulated proteins also impacted muscle morphogenesis (MUSTN1, CSRP3, TMSBX4, PDLIM, CALD1) as well as categories of mitochondria, sarcomere, extracellular matrix/ basement membrane, transcription, translation, cell cycle regulation, neurons amongst others. Downregulated DEP primarily impacted mitochondria, the sarcomere and glycogen metabolism. Notably, unlike human myotonic dystrophy, trinucleotide repeat expansions were not found in the DMPK 3'UTR (CTG)n nor tetranucleotide repeat expansions (CCTG)n in intron 1 of CNBP. Isoforms of CLCN1 containing fetal exon 7 were detected in equal frequency in eMD and control muscle and exon 22 was not alternatively spliced in ATP2A1 as has been found in DM1. Thus, distinct from DM1 and DM2, eMD is driven by unique molecular mechanisms impacting skeletal muscle morphogenesis, neurons and regulation of gene transcription/translation that alter fiber type composition, distribution and morphology. The origin of myotonia does not appear to be driven by a mutation in CLCN1 or retention of exon CLCN 7. Expanded splice site analysis and further research is warranted to elucidate the cause of myotonia and the distinct etiology of eMD.
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
Overview
This research investigates equine myotonic dystrophy (eMD), a rare muscle disorder in horses, by examining muscle fiber composition, gene and protein expression, and genetic features to understand how it differs from human myotonic dystrophy at molecular and cellular levels.
Background and Objectives
Equine myotonic dystrophy (eMD) is a neuromuscular disorder characterized by muscle hypertrophy (enlargement), stiffness, dystrophic muscle changes, and abnormal muscle electrical activity called myotonic discharges.
Human myotonic dystrophy (DM) arises from specific repeat expansions in genes DMPK (DM1) or CNBP (DM2), which cause mRNA processing defects and abnormal gene splicing resulting in disease symptoms.
The study focused on six young eMD-affected Quarter Horses and eight control Quarter Horses to explore differences in:
Muscle fiber types in various muscles (triceps, gluteal, semimembranosus)
Gene and protein expression patterns through transcriptomic and proteomic analyses
Presence of known repeat expansions in DMPK and CNBP genes typical of human DM
Specific alternative splicing events in muscle-related genes (exon 7 retention in CLCN1, exon 22 splicing in ATP2A1)
Key Findings: Muscle Fiber and Molecular Characteristics
Hindlimb muscles of eMD horses showed predominance and clustering of type 1 muscle fibers, which are slow-twitch fibers usually adapted for endurance.
Expression of embryonic myosin was observed, indicating abnormal muscle differentiation or regeneration processes.
Upregulation of numerous mitochondrial and sarcomeric proteins was detected, suggesting changes in energy metabolism and muscle contractile machinery.
Gene Ontology (GO) analysis of 730 upregulated genes revealed enrichment in processes related to the development (“morphogenesis”) of mesodermal tissues, which include skeletal muscle.
Some upregulated genes influence myoD expression, a critical regulator of muscle differentiation.
Neuronal functions, transcription and translation mechanisms, cytoskeletal structure, cell membranes, and calcium regulation
Top upregulated proteins included MUSTN1, CSRP3, TMSBX4, PDLIM, and CALD1, which play roles in muscle morphogenesis, mitochondrial function, sarcomere structure, extracellular matrix and basement membrane organization, transcription, translation, cell cycle, and neuron-related functions.
Downregulated proteins mainly affected mitochondria, sarcomere components, and glycogen metabolism, indicating possible energy utilization issues and structural muscle defects.
Genetic and Splicing Analyses
Unlike human DM, no trinucleotide (CTG)n repeat expansions were found in the 3’ untranslated region (UTR) of the DMPK gene in eMD horses.
No tetranucleotide (CCTG)n repeat expansions were detected in intron 1 of CNBP, another gene linked to human myotonic dystrophy.
Alternative splicing analysis showed that the fetal isoform of the chloride channel gene CLCN1, containing exon 7, appeared equally in eMD and control horses, suggesting no abnormal splicing there.
Similarly, exon 22 of the calcium ATPase gene ATP2A1 was not alternatively spliced in eMD horses, a contrast to human DM1 where it is commonly affected.
Conclusions and Implications
eMD is molecularly distinct from human DM1 and DM2, indicating different underlying mechanisms beyond the known repeat expansions.
The disease involves abnormal skeletal muscle development, altered fiber composition and distribution, and changes in neuronal and gene regulatory pathways.
The cause of myotonia (muscle stiffness) in eMD does not appear to result from mutations or abnormal splicing of CLCN1 or ATP2A1 genes, which are implicated in human myotonia.
Further investigations, including expanded splice site analyses and molecular studies, are needed to identify the specific genetic or molecular triggers of eMD.
Significance
This study enhances understanding of equine myotonic dystrophy by differentiating it from human forms at the molecular level.
It highlights unique molecular signatures affecting muscle morphogenesis and neuronal functions in horses.
The findings encourage further research into novel molecular pathways that may contribute to muscle diseases in animals and possibly provide comparative insights for human muscle disorders.
Cite This Article
APA
Valberg SJ, Williams ZJ, Ames EG, Mickelson JR, Nout-Lomas YS, Landolt G, Sanz M, Gardner K.
(2026).
Aberrant skeletal muscle morphogenesis and myofiber differentiation characterize equine myotonic dystrophy.
PLoS One, 21(1), e0341655.
https://doi.org/10.1371/journal.pone.0341655
Michigan State University, Large Animal Clinical Sciences, College of Veterinary Medicine, East Lansing, Michigan, United States of America.
Williams, Zoë J
Department of Pediatrics, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
Ames, Elizabeth G
Department of Pathobiology, College of Veterinary Medicine, University of Minnesota, St Paul, Minnesota, United States of America.
Mickelson, James R
Department of Veterinary Clinical Sciences, Washington State University, Pullman Washington, United States of America.
Nout-Lomas, Yvette S
Department of Pediatrics, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
Landolt, Gabriele
Department of Pediatrics, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
Sanz, Macarena
Department of Veterinary Clinical Sciences, Washington State University, Pullman Washington, United States of America.
Gardner, Keri
Michigan State University, Large Animal Clinical Sciences, College of Veterinary Medicine, East Lansing, Michigan, United States of America.
MeSH Terms
Animals
Myotonic Dystrophy / pathology
Myotonic Dystrophy / genetics
Myotonic Dystrophy / veterinary
Myotonic Dystrophy / metabolism
Horses
Muscle, Skeletal / pathology
Muscle, Skeletal / metabolism
Muscle Fibers, Skeletal / pathology
Muscle Fibers, Skeletal / metabolism
Cell Differentiation
Horse Diseases / genetics
Horse Diseases / pathology
Horse Diseases / metabolism
Myotonin-Protein Kinase / genetics
Morphogenesis / genetics
Trinucleotide Repeat Expansion
Conflict of Interest Statement
Dr. Valberg directs the Neuromuscular Diagnostic Laboratory and receives financial remuneration for interpreting muscle biopsies. She also received royalties for genetic tests PSSM1 and GBED and feed products for horses. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
References
This article includes 83 references
Valberg SJ. Disorders of the musculoskeletal system. 2018. 542–79.
Hehir MK, Logigian EL. Electrodiagnosis of myotonic disorders. Phys Med Rehabil Clin N Am 2013;24(1):209–20.
Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan Y, Moxley RT. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet 2006;15(13):2087–97.
López-Martínez A, Soblechero-Martín P, de-la-Puente-Ovejero L, Nogales-Gadea G, Arechavala-Gomeza V. An overview of alternative splicing defects implicated in myotonic dystrophy type I. Genes (Basel) 2020;11(9):1109.
Furling D, Lam LT, Agbulut O, Butler-Browne GS, Morris GE. Changes in myotonic dystrophy protein kinase levels and muscle development in congenital myotonic dystrophy. Am J Pathol 2003;162(3):1001–9.
Frey N, Barrientos T, Shelton JM, Frank D, Rütten H, Gehring D. Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress. Nat Med 2004;10(12):1336–43.
van Gorp PRR, Zhang J, Liu J, Tsonaka R, Mei H, Dekker SO. Sbk2, a newly discovered atrium-enriched regulator of sarcomere integrity.. Circ Res 2022;131(1):24–41.
Liu Y, Shang Y, Yan Z, Li H, Wang Z, Liu Z. Pim1 kinase positively regulates myoblast behaviors and skeletal muscle regeneration.. Cell Death Dis 2019;10(10):773.
Nakayama Y, Nara N, Kawakita Y, Takeshima Y, Arakawa M, Katoh M. Cloning of cDNA encoding a regeneration-associated muscle protease whose expression is attenuated in cell lines derived from Duchenne muscular dystrophy patients.. Am J Pathol 2004;164(5):1773–82.
Xu Z, Liu Z, He X, Shu H, Wang X, Liu T. Investigation of the transcriptome and metabolome of the cerebral cortex and testes in Cntnap4-deficient mice.. J Psychiatr Res 2025;186:252–62.
Heinz LX, Rebsamen M, Rossi DC, Staehli F, Schroder K, Quadroni M. The death domain-containing protein Unc5CL is a novel MyD88-independent activator of the pro-inflammatory IRAK signaling cascade.. Cell Death Differ 2012;19(4):722–31.
Manterola M, Brown TM, Oh MY, Garyn C, Gonzalez BJ, Wolgemuth DJ. BRDT is an essential epigenetic regulator for proper chromatin organization, silencing of sex chromosomes and crossover formation in male meiosis.. PLoS Genet 2018;14(3):e1007209.
Kim S-D, Liu JL, Roscioli T, Buckley MF, Yagnik G, Boyadjiev SA. Leucine-rich repeat, immunoglobulin-like and transmembrane domain 3 (LRIT3) is a modulator of FGFR1.. FEBS Lett 2012;586(10):1516–21.
Tajbakhsh S, Borello U, Vivarelli E, Kelly R, Papkoff J, Duprez D. Differential activation of Myf5 and MyoD by different Wnts in explants of mouse paraxial mesoderm and the later activation of myogenesis in the absence of Myf5.. Development 1998;125(21):4155–62.
Nagakura R, Yamamoto M, Jeong J, Hinata N, Katori Y, Chang W-J. Switching of Sox9 expression during musculoskeletal system development.. Sci Rep 2020;10(1):8425.
Han D, Zhao H, Parada C, Hacia JG, Bringas P Jr, Chai Y. A TGFβ-Smad4-Fgf6 signaling cascade controls myogenic differentiation and myoblast fusion during tongue development.. Development 2012;139(9):1640–50.
McDermott A, Gustafsson M, Elsam T, Hui C-C, Emerson CP, Borycki AGl. Gli2 and Gli3 have redundant and context-dependent function in skeletal muscle formation.. 2005.
Jang S-M, Kim J-W, Kim D, Kim C-H, An J-H, Choi K-H. Sox4-mediated caldesmon expression facilitates differentiation of skeletal myoblasts.. J Cell Sci 2013;126(Pt 22):5178–88.
Pan Z, Du G, Li G, Wu D, Chen X, Geng Z. Apolipoprotein H: a novel regulator of fat accumulation in duck myoblasts.. J Anim Sci Technol 2022;64(6):1199–214.
Sewry CA, Feng L, Chambers D, Matthews E, Phadke R. Importance of immunohistochemical evaluation of developmentally regulated myosin heavy chains in human muscle biopsies.. Neuromuscul Disord 2021;31(5):371–84.
Law C, Cheung P. Expression of Non-acetylatable H2A.Z in myoblast cells blocks myoblast differentiation through disruption of MyoD Expression.. J Biol Chem 2015;290(21):13234–49.
Liu C, Gersch RP, Hawke TJ, Hadjiargyrou M. Silencing of Mustn1 inhibits myogenic fusion and differentiation.. Am J Physiol Cell Physiol 2010;298(5):C1100-8.
Brack AS, Conboy IM, Conboy MJ, Shen J, Rando TA. A temporal switch from notch to Wnt signaling in muscle stem cells is necessary for normal adult myogenesis.. Cell Stem Cell 2008;2(1):50–9.
Wang M-Y, Yang J-M, Wu Y, Li H, Zhong Y-B, Luo Y. Curcumin-activated Wnt5a pathway mediates Ca2+ channel opening to affect myoblast differentiation and skeletal muscle regeneration.. J Cachexia Sarcopenia Muscle 2024;15(5):1834–49.
Sun Q, Zhang Y, Yang G, Chen X, Zhang Y, Cao G. Transforming growth factor-beta-regulated miR-24 promotes skeletal muscle differentiation.. Nucleic Acids Res 2008;36(8):2690–9.
Liu D, Black BL, Derynck R. TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3.. Genes Dev 2001;15(22):2950–66.
Dubowitz V, Sewry CA, Oldfors A. Muscle biopsy: a practical approach. 2020.
Stark DA, Coffey NJ, Pancoast HR, Arnold LL, Walker JPD, Vallée J. Ephrin-A3 promotes and maintains slow muscle fiber identity during postnatal development and reinnervation.. J Cell Biol 2015;211(5):1077–91.
Nozawa K, Lin Y, Kubodera R, Shimizu Y, Tanaka H, Ohshima T. Zebrafish Mecp2 is required for proper axonal elongation of motor neurons and synapse formation.. Dev Neurobiol 2017;77(9):1101–13.
Yang J, Dominguez B, de Winter F, Gould TW, Eriksson JE, Lee K-F. Nestin negatively regulates postsynaptic differentiation of the neuromuscular synapse.. Nat Neurosci 2011;14(3):324–30.
Vihola A, Bachinski LL, Sirito M, Olufemi S-E, Hajibashi S, Baggerly KA. Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2.. Acta Neuropathol 2010;119(4):465–79.
Bardouille C, Vullhorst D, Jockusch H. Expression of chloride channel 1 mRNA in cultured myogenic cells: a marker of myotube maturation.. FEBS Lett 1996;396(2–3):177–80.
Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol 2019;37(8):907–15.
Pertea M, Pertea GM, Antonescu CM, Chang T-C, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol 2015;33(3):290–5.
Rappsilber J, Mann M, Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2007;2(8):1896–906.
Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003;75(17):4646–58.
Oberg AL, Mahoney DW, Eckel-Passow JE, Malone CJ, Wolfinger RD, Hill EG. Statistical analysis of relative labeled mass spectrometry data from complex samples using ANOVA. J Proteome Res 2008;7(1):225–33.